Jim Gibson to join PacBio as Chief Financial Officer
Globe Newswire (Thu, 27-Mar 9:05 AM ET)
Globe Newswire (Mon, 17-Mar 9:05 AM ET)
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference
Globe Newswire (Wed, 19-Feb 4:05 PM ET)
PacBio Grants Equity Incentive Award to New Employee
Globe Newswire (Fri, 14-Feb 11:09 PM ET)
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
Globe Newswire (Thu, 13-Feb 4:05 PM ET)
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service
Globe Newswire (Mon, 3-Feb 9:05 AM ET)
PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025
Globe Newswire (Thu, 30-Jan 4:05 PM ET)
PacBio Announces Appointment of Chris Smith to Board of Directors
Globe Newswire (Thu, 30-Jan 9:05 AM ET)
PacBio Technology Powers Landmark Multiomic Study Published in Nature Genetics
Globe Newswire (Wed, 29-Jan 9:05 AM ET)
PacBio Names Global Institute for Food Security as Canada's First Revio Certified Service Provider
Globe Newswire (Thu, 23-Jan 9:05 AM ET)
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Pacific Biosciences Of California trades on the NASDAQ stock market under the symbol PACB.
As of April 3, 2025, PACB stock price declined to $1.19 with 5,809,709 million shares trading.
PACB has a beta of 2.31, meaning it tends to be more sensitive to market movements. PACB has a correlation of 0.07 to the broad based SPY ETF.
PACB has a market cap of $354.44 million. This is considered a Small Cap stock.
Last quarter Pacific Biosciences Of California reported $39 million in Revenue and -$.20 earnings per share. This fell short of revenue expectation by $-936,000 and exceeded earnings estimates by $.01.
In the last 3 years, PACB traded as high as $14.55 and as low as $1.08.
The top ETF exchange traded funds that PACB belongs to (by Net Assets): ARKK, ARKG, VTI, IWM, VXF.
PACB has underperformed the market in the last year with a return of -65.1%, while the SPY ETF gained +4.8%. In the last 3 month period, PACB fell short of the market, returning -33.9%, while SPY returned -7.9%. However, in the most recent 2 weeks PACB has outperformed the stock market by returning -4.8%, while SPY returned -5.1%.
PACB support price is $1.20 and resistance is $1.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PACB shares will trade within this expected range on the day.